CTX-II

Meridian Valley Lab measures CTX-II in a single, convenient urine collection to assess cartilage damage and bone turnover due to arthritis or heavy exercise. The detection of arthritis during the early stages, with accurate and reliable biomarkers such as urinary CTX-II, can help preserve joint function, decrease pain, and prevent disease progression through early intervention. Human studies indicate that CTX-II can distinguish rapidly progressive osteoarthritis better than other urinary markers such as deoxypyridinoline (DPD).